Biomarker associations of immune checkpoint inhibitor versus chemotherapy effectiveness in first-line metastatic endometrial carcinomas: A real-world study.
Santin A, Graf R, Shah K, Kelly A, Danziger N, Lin D, Oxnard G, Elvin J. Biomarker associations of immune checkpoint inhibitor versus chemotherapy effectiveness in first-line metastatic endometrial carcinomas: A real-world study. Journal Of Clinical Oncology 2022, 40: 5596-5596. DOI: 10.1200/jco.2022.40.16_suppl.5596.Peer-Reviewed Original ResearchSingle-agent immune checkpoint inhibitorsImmune checkpoint inhibitorsTumor mutational burdenCheckpoint inhibitorsMEC patientsChemotherapy effectivenessMSI statusAnti-PD1 immune checkpoint inhibitorsFirst-line immune checkpoint inhibitorsMultivariable Cox proportional hazards modelsCox proportional hazards modelMetastatic endometrial carcinomaOverall survival comparisonEndometrial carcinoma patientsMut/MbProportional hazards modelReal-world studyPrespecified analysis planHazard ratioStandard chemotherapyCarcinoma patientsEndometrial carcinomaPredictive biomarkersChemotherapy treatmentFavorable outcome